Abstract:The oral bioavailability of Sirolimus is limited by poor dissolution of the compound in the gastrointestinal tract resulting in a low bioavailability and large inter-individual differences in blood levels. Several different formulation approaches were applied to overcome these disadvantageous pharmacokinetic properties including the marketed oral solution and a tablet form containing wet milled nanocrystals. These approaches deliver improved pharmacokinetics, yet, they share the characteristics of complex production method and composition. We have developed a nanostructured Sirolimus formulation prepared by the controlled continuous flow precipitation of the compound from its solution in the presence of stabilizers. We have shown that contrary to the batch production the process could be easily intensified and scaled up; apparently the uniformity of the precipitation is heavily dependent on the production parameters, most likely the mixing of the solvent and antisolvent. We compared the physicochemical and pharmacokinetic properties of the nanostructured formula with the marketed nanoformula. We found that our method produces particles in the size range of less than 100nm. The solid form redispersed instantaneously in water and in biorelevant media. Both the solid form and the redispersed colloid solution showed excellent stability even in accelerated test conditions. The oral administration of the nanostructured formula resulted in faster absorption, higher exposure and higher trough concentrations when compared to the marked form. These advantageous properties could allow the development of solid oral Sirolimus formulae with lower strength and gel based topical delivery systems.

Correction to: Effect of Surface Property on the Release and Oral Absorption of Solid Sirolimus-Containing Self-Microemulsifying Drug Delivery System

Correction: Synthetic Ultra-Long Chain Fatty Acyl Based Amphiphilic Lipids As a Dual Function Excipient for the Production of Surfactant-Free Solid Lipid Nanoparticles (Sf-Slns): a Physico-Chemical Study

Effect of Surface Property on the Release and Oral Absorption of Solid Sirolimus-Containing Self-microemulsifying Drug Delivery System

Author Correction to ‘Amino-Functionalized Poloxamer 407 with Both Mucoadhesive and Thermosensitive Properties: Preparation, Characterization and Application in Vaginal Drug Delivery System’ [acta Pharm Sin B 7 (2017) 593–602]

Correction: A Novel Biocompatible, Simvastatin-Loaded, Bone-Targeting Lipid Nanocarrier for Treating Osteoporosis More Effectively

Correction: Facile Preparation of Phospholipid-Amorphous Calcium Carbonate Hybrid Nanoparticles: Toward Controllable Burst Drug Release and Enhanced Tumor Penetration.

Correction: Oral delivery of a platinum anticancer drug using lipid assisted polymeric nanoparticles

Correction: Ci et al. Enhanced Delivery of Imatinib into Vaginal Mucosa via a New Positively Charged Nanocrystal-Loaded in Situ Hydrogel Formulation for Treatment of Cervical Cancer. Pharmaceutics 2019, 11, 15

Correction: A ternary system of meloxicam with matching hydrophilic polymer and cyclodextrin for improved stability in liquid preprations

Codelivery of Doxorubicin and MDR1-siRNA by Mesoporous Silica Nanoparticles-Polymerpolyethylenimine to Improve Oral Squamous Carcinoma Treatment [Corrigendum]

Correction to: “Synthesis of Chitosan/Diatomite Composite as an Advanced Delivery System for Ibuprofen Drug; Equilibrium Studies and the Release Profile”

Correction: Bioreducible and acid-labile polydiethylenetriamines with sequential degradability for efficient transgelin-2 siRNA delivery

Author Correction: The softness of tumour-cell-derived microparticles regulates their drug-delivery efficiency

Sirolimus Solid Self-Microemulsifying Pellets: Formulation Development, Characterization and Bioavailability Evaluation.

Correction to "Co-Delivery of Astaxanthin and si TGF-β 1 via Ionizable Liposome Nanoparticles for Improved Idiopathic Pulmonary Fibrosis Therapy"

Correction: Yang et al. Construction and Evaluation of Chitosan-Based Nanoparticles for Oral Administration of Exenatide in Type 2 Diabetic Rats. Polymers 2022, 14, 2181

Correction: A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy

Correction: An ultrasound-induced MXene doped PAM–SA super-tough hydrogel

Correction: Co-delivery of anionic epitope/CpG vaccine and IDO inhibitor by self-assembled cationic liposomes for combination melanoma immunotherapy

Sirolimus formulation with improved pharmacokinetic properties produced by a continuous flow method